Insulin Pump
Racial-ethnic, insurance-mediated bias common when recommending diabetes devices
More than 60% of diabetes providers display implicit insurance-mediated bias, and more than one-third have racial-ethnic bias when recommending diabetes technology, according to study data published in Diabetes Technology & Therapeutics.
DIY artificial pancreas increases time in range vs. pump therapy in type 1 diabetes
NEW ORLEANS — Adults and children with type 1 diabetes who used an open-source automated insulin delivery system significantly increased time in target glucose range compared with baseline and with sensor-augmented pump therapy.
Extended-wear insulin infusion set lasts 7 days for most wearers, with few adverse events
A novel extended-wear insulin infusion set was usable for up to 7 days for most adults with type 1 diabetes, with no change in glycemic control and few adverse events, according to findings published in Diabetes Technology & Therapeutics.
Top in endocrinology: Weight loss drug; initiating insulin pump therapy in primary care
Topline data from the SURMOUNT-1 trial showed that once-weekly treatment with tirzepatide reduced weight among adults with overweight or obesity.
Insulin pump therapy can be initiated in primary care
Susan Weiner, MS, RDN, CDCES, FADCES, talks with Michael Heile, MD, FAAFP, BC-ADM, a primary care physician and person living with type 1 diabetes, about the benefits of insulin pump therapy for people with type 2 diabetes who use insulin.
Fear, medical mistrust may cause disparities in diabetes device uptake for Black youths
Black adolescents with type 1 diabetes and their parents believe fear, lack of exposure and mistrust of the medical community are some of the reasons racial disparities exist with diabetes device use, according to study findings.
FDA approves first smartphone app for bolus insulin delivery
The FDA has approved the first smartphone application capable of initiating insulin delivery for insulin pump wearers, according to a company press release.
Better time in range with closed-loop therapy for older adults with type 1 diabetes
Closed-loop insulin pump therapy is associated with more time in range compared with sensor-augmented therapy among older adults with type 1 diabetes, according to study findings published in Diabetes Care.
FDA clears first tubeless hybrid closed-loop insulin delivery system
The FDA has cleared the first tubeless hybrid closed-loop insulin delivery system for people with type 1 diabetes aged 6 years and older, according to a press release from Insulet.
Targeted diabetes education improves self-reported health in underserved community
Diabetes education guides targeted toward a group of low-income, predominantly Hispanic adults from an underserved community in Los Angeles were associated with improved perceived health and diabetes knowledge, according to study data.